company background image
VMD

Vimedimex Medi-Pharma HOSE:VMD Stock Report

Last Price

₫22.50k

Market Cap

₫47.0t

7D

1.1%

1Y

-8.9%

Updated

07 Aug, 2022

Data

Company Financials
VMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

VMD Stock Overview

Vimedimex Medi-Pharma Joint Stock Company provides pharmaceutical distribution.

Risk Analysis

Has not reported any financial data


Vimedimex Medi-Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vimedimex Medi-Pharma
Historical stock prices
Current Share Price₫22,500.00
52 Week High₫88,100.00
52 Week Low₫19,800.00
Beta0
1 Month Change1.12%
3 Month Change7.14%
1 Year Change-8.91%
3 Year Change14.21%
5 Year Change-20.50%
Change since IPO-29.69%

Recent News & Updates

Shareholder Returns

VMDVN HealthcareVN Market
7D1.1%1.0%3.7%
1Y-8.9%-20.3%-7.0%

Return vs Industry: VMD exceeded the VN Healthcare industry which returned -20.3% over the past year.

Return vs Market: VMD underperformed the VN Market which returned -7% over the past year.

Price Volatility

Is VMD's price volatile compared to industry and market?
VMD volatility
VMD Average Weekly Movement7.8%
Healthcare Industry Average Movement5.2%
Market Average Movement7.4%
10% most volatile stocks in VN Market10.0%
10% least volatile stocks in VN Market4.2%

Stable Share Price: VMD is not significantly more volatile than the rest of VN stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: VMD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1984n/aPham Senhttps://www.vietpharm.com.vn

Vimedimex Medi-Pharma Joint Stock Company provides pharmaceutical distribution. The company also offers GSP warehouse, bonded warehouse, and general warehouse for rent; and import and export and distribution of pharmaceuticals products, such as medicine and pharmacy, agricultural products, spices, and food. It also invest in office buildings.

Vimedimex Medi-Pharma Fundamentals Summary

How do Vimedimex Medi-Pharma's earnings and revenue compare to its market cap?
VMD fundamental statistics
Market Cap₫47.02t
Earnings (TTM)₫0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VMD income statement (TTM)
Revenue₫0
Cost of Revenue₫0
Gross Profit₫0
Other Expenses₫0
Earnings₫0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did VMD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VMD?

Other financial metrics that can be useful for relative valuation.

VMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does VMD's PB Ratio compare to its peers?

VMD PB Ratio vs Peers
The above table shows the PB ratio for VMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.6x
301060 Shanghai Labway Clinical Laboratory
7.7xn/aCN¥13.4b
7476 AS ONE
3.9x9.7%JP¥248.6b
9987 Suzuken
0.7x9.4%JP¥303.8b
3360 Ship Healthcare Holdings
2.1x8.5%JP¥243.4b
VMD Vimedimex Medi-Pharma
n/an/a₫47.0t

Price-To-Book vs Peers: Insufficient data to calculate VMD's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does VMD's PE Ratio compare vs other companies in the Asian Healthcare Industry?

Price-To-Book vs Industry: Insufficient data to calculate VMD's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is VMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VMD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VMD's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of VMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VMD's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of VMD's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Future Growth

How is Vimedimex Medi-Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.6%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vimedimex Medi-Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of VMD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Vimedimex Medi-Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.3%

Historical Healthcare annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Vimedimex Medi-Pharma has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Discover strong past performing companies

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Vimedimex Medi-Pharma's management and board experience and expertise to assess their ability to deliver on their strategic promises.

Financial Health

How is Vimedimex Medi-Pharma's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Vimedimex Medi-Pharma's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Vimedimex Medi-Pharma has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Discover healthy companies

  • Take a look at our analysis of VMD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Vimedimex Medi-Pharma's financial data was last updated here.

Dividend

What is Vimedimex Medi-Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VMD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VMD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Pham Sen

2.58yrs

Tenure

Ms. Pham Thi Sen has been Chief Executive Officer of Vimedimex Medi-Pharma Joint Stock Company since January 1, 2020 and was its Deputy Chief Executive Officer since March 1, 2018 until January 1, 2020.


Leadership Team

Experienced Management: VMD's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: VMD's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vimedimex Medi-Pharma Joint Stock Company's employee growth, exchange listings and data sources


Key Information

  • Name: Vimedimex Medi-Pharma Joint Stock Company
  • Ticker: VMD
  • Exchange: HOSE
  • Founded: 1984
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: ₫47.024t
  • Shares outstanding: 2.09b
  • Website: https://www.vietpharm.com.vn

Location

  • Vimedimex Medi-Pharma Joint Stock Company
  • Vimedimex Group
  • 8th Floor
  • Ha Noi
  • Vietnam

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.